For ovarian malignancies, oocyte retrieval is better out of the body

For ovarian malignancies, oocyte retrieval is better out of the body
Each year, nearly 100,000 women in the United States are diagnosed with gynecologic malignancies. According to Surveillance, Epidemiology and End Results (SEER) statistics, approximately 12% of ovarian malignancies affect reproductive-age women (1). Although fertility-sparing surgery is an option for women with ovarian cancer with early-stage disease confined to one ovary, the standard treatment typically includes hysterectomy, bilateral salpingo-oophorectomy, staging with pelvic and para-aortic lymphadenectomy, and adjuvant chemotherapy in most cases (2).
Source: fertstert.org